The latest price target for Biohaven (NYSE:BHVN) was reported by TD Cowen on March 11, 2026. The analyst firm set a price target for $30.00 expecting BHVN to rise to within 12 months (a possible 220.51% upside). 30 analyst firms have reported ratings in the last year.

The latest analyst rating for Biohaven (NYSE:BHVN) was provided by TD Cowen, and Biohaven maintained their buy rating.

The last upgrade for Biohaven Ltd happened on January 21, 2026 when RBC Capital raised their price target to $22. RBC Capital previously had a sector perform for Biohaven Ltd.

The last downgrade for Biohaven Ltd happened on December 3, 2025 when HC Wainwright & Co. changed their price target from $30 to $11 for Biohaven Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biohaven, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biohaven was filed on March 11, 2026 so you should expect the next rating to be made available sometime around March 11, 2027.

While ratings are subjective and will change, the latest Biohaven (BHVN) rating was a maintained with a price target of $15.00 to $30.00. The current price Biohaven (BHVN) is trading at is $9.36, which is out of the analyst’s predicted range.